Type 2 Diabetes News and Research

Latest Type 2 Diabetes News and Research

Experts to review latest research on bariatric surgery at International summit

On March 28, leading experts across multiple disciplines will convene at the 2nd World Congress on Interventional Therapies for Type 2 Diabetes to review the latest research on bariatric surgery as a treatment option.

17 Mar 2011

Researchers discover molecular switch for insulin secretion

16 Mar 2011

Discovery of molecular switch for the secretion of insulin

Johns Hopkins researchers believe they have uncovered the molecular switch for the secretion of insulin — the hormone that regulates blood sugar — providing for the first time an explanation of this process. In a report published online March 1 in Cell Metabolism, the researchers say the work solves a longtime mystery and may lead to better treatments for type 2 diabetes, the most common form of the disease.

15 Mar 2011

Type 2 diabetes drug less likely to cause weight gain, raise cholesterol levels

An inexpensive type 2 diabetes drug that has been around for more than 15 years works just as well and has fewer side effects than a half-dozen other, mostly newer and more expensive classes of medication used to control the chronic disease, new Johns Hopkins research suggests.

15 Mar 2011

National clinical DPTT to help improve diabetes control

The Stony Brook University School of Dental Medicine is leading a multicenter national clinical trial to evaluate whether treatment of chronic periodontitis will help improve diabetes control. Sponsored by the National Institutes of Health, the Diabetes and Periodontal Therapy Trial monitors blood sugar levels of those with Type 2 diabetes after periodontal therapy.

15 Mar 2011

Biodel selects BIOD-105, BIOD-107 recombinant human insulin formulations for clinical testing, development

Biodel Inc. announced today that it has selected two new formulations of recombinant human insulin for clinical testing and is accelerating clinical development plans of these mealtime insulin drug candidates. The new formulations, BIOD-105 and BIOD-107, are designed to result in more rapid insulin action compared to currently marketed meal time insulin analogs while maintaining an injection site tolerability profile comparable to currently marketed insulins.

14 Mar 2011

Life Technologies receives FDA 510(k) clearance for StemPro MSC SFM device

Life Technologies Corporation today announced it has received FDA 510(k) clearance for StemPro MSC SFM – a first for this next-generation stem cell culture medium that is now cleared as a medical device and satisfies a crucial requirement for researchers involved in clinical trials in the United States.

14 Mar 2011

New study identifies 15 genetic regions underlying primary biliary cirrhosis

Researchers have provided new clues into the genetics underlying a chronic form of liver disease, called primary biliary cirrhosis, which can lead to transplant surgery for patients.

14 Mar 2011

Otelixizumab Phase 3 DEFEND-1 study in new-onset autoimmune type 1 diabetes does not meet primary endpoint

Tolerx, Inc. and GlaxoSmithKline (GSK) today announced that the Phase 3 DEFEND-1 study of otelixizumab, an investigational humanized anti-CD3 monoclonal antibody, did not meet the primary efficacy endpoint of change in C-peptide at month 12 in patients with new-onset autoimmune type 1 diabetes.

11 Mar 2011

Arena fourth quarter net loss decreases to $28.2 million

Arena Pharmaceuticals, Inc. today reported financial results for the fourth quarter and full year ended December 31, 2010, and reviewed recent developments.

11 Mar 2011

Halozyme Therapeutics 2010 net loss decreases to $53.2 million

Halozyme Therapeutics, Inc., a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the endocrinology, oncology, dermatology and drug delivery markets, today reported financial results for the fourth quarter and year ended December 31, 2010.

11 Mar 2011

Genentech announces positive outcomes from Lucentis Phase III trial against DME

Genentech, a member of the Roche Group, today announced that two-year results from a pivotal Phase III trial showed patients with diabetic macular edema who received Lucentis experienced rapid and sustained improvement in vision compared to those who received a placebo injection.

11 Mar 2011

Positive results from exenatide phase 2 study in patients with type 2 diabetes

Amylin Pharmaceuticals, Inc., Eli Lilly and Company and Alkermes, Inc. today announced positive results from a phase 2 study evaluating the effects of a once-monthly injectable suspension formulation of exenatide on glycemic control in patients with type 2 diabetes.

10 Mar 2011

Mother's poor or inadequate nutrition linked to overeating later in life

Providing further understanding of the link between low birth weights and obesity later in life, researchers found nutritionally deprived newborns are "programmed" to eat more because they develop less neurons in the region of the brain that controls food intake, according to an article published today in the journal, Brain Research.

10 Mar 2011

Tiniest pollution particles can contribute to cardiovascular disease in diabetic people

Scientists are untangling how the tiniest pollution particles - which we take in with every breath we breathe - affect our health, making people more vulnerable to cardiovascular and respiratory problems.

10 Mar 2011

FDA accepts BMY and AstraZeneca's dapagliflozin NDA for review

Bristol-Myers Squibb Company and AstraZeneca today announced that the U.S. Food and Drug Administration has accepted for review a New Drug Application for dapagliflozin, an investigational compound for the treatment of adults with type 2 diabetes mellitus.

9 Mar 2011

Diabetes belt mapped out in the US

A government commissioned team of researchers has now identified a diabetes belt in the U.S. County-by-county mapping shows that the highest rates of diabetes cut two paths - one strung through Tennessee, Kentucky and West Virginia, and another running eastward from Louisiana through Mississippi, Alabama, Georgia and South Carolina. This belt also touches parts of North Carolina, Virginia, Florida, Texas, Arkansas, Ohio and Pennsylvania. High-diabetes pockets crop up in Oklahoma, Michigan, Arizona, the Dakotas and elsewhere. The belt includes 644 counties in 15 states with the highest diabetes rates.

8 Mar 2011

George Brown College works with MEMOTEXT for developing new patient adherence program

George Brown College is collaborating with MEMOTEXT, a patient adherence and medication compliance company, to develop an inference-based telephone/short message service (SMS) based communications program for an overseas health stakeholder-based research project.

8 Mar 2011

First POSE procedure using USGI's Incisionless Operating Platform performed at Ospedale All'Angelo

USGI Medical, Inc. announced that a prominent surgeon in Italy performed the first POSE procedure on patients for weight loss.

8 Mar 2011

Klotho protein discovery can lead to new class of drugs for treatment of obesity

An important discovery in mice may make a big difference in people's waistlines thanks to a team of Harvard scientists who found that reducing the function of a transmembrane protein, called Klotho, in obese mice with high blood sugar levels produced lean mice with reduced blood sugar levels.

8 Mar 2011